Abstract: Provided are formulations comprising therapeutically effective amounts of ambrisentan or a pharmaceutically acceptable salt thereof and tadalafil or a pharmaceutically acceptable salt thereof and methods of treating and/or preventing pulmonary hypertension by administration of the formulations.

Abstract: Provided are formulations comprising therapeutically effective amounts of ambrisentan or a pharmaceutically acceptable salt thereof and tadalafil or a pharmaceutically acceptable salt thereof and methods of treating and/or preventing pulmonary hypertension by administration of the formulations.

Abstract: The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.

Abstract: The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.

Abstract: Provided are formulations comprising therapeutically effective amounts of ambrisentan or a pharmaceutically acceptable salt thereof and tadalafil or a pharmaceutically acceptable salt thereof and methods of treating and/or preventing pulmonary hypertension by administration of the formulations.

Abstract: The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.

Abstract: The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.

Abstract: The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.

Abstract: Provided are formulations comprising therapeutically effective amounts of ambrisentan or a pharmaceutically acceptable salt thereof and tadalafil or a pharmaceutically acceptable salt thereof and methods of treating and/or preventing pulmonary hypertension by administration of the formulations.

Abstract: The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.

Abstract: The present invention relates to a method for reducing the toxicity of cardiac glycosides comprising the coadministration of a therapeutically effective amount of cardiac glycoside and a therapeutically effective amount ranolazine. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.

Abstract: The invention is directed to methods for enhancing endogenous insulin levels in a patient in need thereof which method comprises administering to the patient an insulin secretion-enhancing amount of racemic ranolazine or the R- or S-enantiomer of ranolazine. It is also directed to methods of treatment comprising racemic ranolazine or the R- or S-enantiomer of ranolazine for enhancing endogenous insulin levels in a patient in need thereof. It is also directed to a composition comprising an insulin secretion-enhancing amount of racemic ranolazine or the R- or S-enantiomer of ranolazine and at least one anti-diabetic agent.

Abstract: The present invention relates to a method for the treatment of atrial fibrillation comprising the coadministration of a synergistic therapeutically effective amount of amiodarone and synergistic therapeutically effective amount ranolazine. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.

Abstract: This invention relates to methods for treating a patient suffering from neuropathic or nociceptive pain which may be mechanical, visceral, and/or inflammatory in nature, comprising administering a therapeutically effective amount of Ranolazine to a patient in need thereof.

Abstract: The invention is directed to methods for enhancing endogenous insulin levels in a patient in need thereof which method comprises administering to the patient an insulin secretion-enhancing amount of racemic ranolazine or the R- or S-enantiomer of ranolazine. It is also directed to methods of treatment comprising racemic ranolazine or the R- or S-enantiomer of ranolazine for enhancing endogenous insulin levels in a patient in need thereof. It is also directed to a composition comprising an insulin secretion-enhancing amount of racemic ranolazine or the R- or S-enantiomer of ranolazine and at least one anti-diabetic agent.

Abstract: A universal mount for tire rims includes a plurality of clips mounted on the inside periphery of a wheel cover. An alternate first type of clip is a clip member mounted in a clip housing and spring loaded with an arcuate proximal termination portion designed to fit over a peripheral surface on a wheel. Opposite vertical spaced apart channels contain coil springs. As the clip member is raised, the springs are compressed and assist in holding the proximal portion over a wheel rim. In a second type of clip, the arcuate proximal termination portion has a vertical wall attached at right angles to a plate that contains a threaded screw. A lower portion of the clip member has a pair of feet that can press down on a pair of coil springs in a pair of vertical chambers. The threaded screw prevents free vertical movements of the clip member. The second alternate type of clip is used to positively lock a wheel cover over a peripheral surface of a wheel rim.

Abstract: A universal mount for tire rims includes a plurality of clips mounted peripherally of a wheel cover. A first type of clip consists of a clip member mounted in a clip housing guided in linear movements on a shaft and having a distal end with an arcuate termination designed to fit over a peripheral surface on a wheel. The proximal end of the clip member has an undulating portion with each horizontal surface having a hole, the holes being aligned with one another so that a guide shaft may extend through the holes to guide the clip member in vertical movements. Also mounted on the shaft are two coil springs, one mounted above the proximal end of the clip member, and one mounted below the proximal end of the clip member. In a second type of clip, the shaft is threaded and holes in the proximal undulating portion of the clip member are threaded and receive the threaded shaft. In this way, the threaded shaft prevents free vertical movements of the clip member.